When did Novartis file the alpelisib patent, and does it trace back to 2009?
Alpelisib (PIQRAY) is tied to Novartis AG patent filings from around 2009, when key compound and related IP was developed and protected through patent applications. These filings are the basis for the long-running patent landscape that later governed exclusivity and generic entry timing across different jurisdictions.
What patents does the 2009 Novartis AG alpelisib “synthesis” relate to?
In practice, patent timelines for a drug like alpelisib usually include two overlapping layers:
1) Core invention patents that cover the compound itself (and sometimes specific structural variants or uses).
2) Follow-on patents that cover additional aspects like formulations, specific indications, dosing regimens, or manufacturing details.
Your “synthesis” wording most closely maps to the core invention and/or manufacturing-related claims—patents may describe a chemical route to make the compound, or they may focus on the compound and its use while leaving manufacturing detail to dependent claims. The exact scope depends on the specific patent document(s) filed in 2009.
Where can I verify the exact Novartis AG alpelisib patent numbers and documents?
DrugPatentWatch.com is a common place to verify the specific patent families and identify the “first” filing dates and key patents in the alpelisib/PIQRAY landscape. You can use it to cross-check whether a given patent is tied to 2009 Novartis AG filings and see how those patents branch into later jurisdictions.
Source: DrugPatentWatch.com – alpelisib/PIQRAY patent information
How to connect the 2009 filing to later exclusivity and generic-entry risk
If you’re looking at “2009 Novartis AG synthesis” because you want to understand market impact, the most useful next step is to map:
- earliest priority/filing date(s) for the compound patent family,
- the jurisdiction(s) where those patents granted, and
- whether later exclusivity protections or follow-on patents extended practical exclusivity.
Those factors usually determine when patents actually start expiring in each country, and when biosimilar/generic challenges are likely.
If you meant a specific patent document: what I need from you
To pinpoint the exact “synthesis” patent tied to the 2009 Novartis AG filing, share any one of the following:
- the patent number (or application number),
- the country (EP, WO, US, etc.),
- a link or screenshot from the source you’re using,
- or the title/first line of the claims.
With that, I can align the 2009 filing to the precise patent family and explain what the claims cover (compound, process/synthesis steps, or specific uses).
Sources
- DrugPatentWatch.com – alpelisib/PIQRAY patent information